PRESENTATION
Q2 2023 — Results presentation
Q2 2023PDF · 30 pages2.3 MB
1 -- 1 of 30 -- 2nd Quarter 2023 Earnings Call July 20, 2023 -- 2 of 30 -- Cautionary Note on Forward-looking Statements This presentation contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, market position and business strategy, and the anticipated separation of the Company’s Consumer Health business. The viewer is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the company to successfully execute strategic plans, including restructuring plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health care industry by government agencies; the Company’s ability to satisfy the necessary conditions to consummate the separation of the Company’s Consumer Health business on a timely basis or at all; the Company’s ability to successfully separate the Company’s Consumer Health business and realize the anticipated benefits from the separation; and the New Consumer Health Company’s ability to succeed as a standalone publicly traded company. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 1, 2023, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this presentation speaks only as of the date of this presentation. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. Cautionary Note on Non-GAAP Financial Measures This presentation refers to certain non-GAAP financial measures. These non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the Company’s website at www.investor.jnj.com/sales-earnings.cfm. 3 -- 3 of 30 -- Immunology REMICADE and SIMPONI/ SIMPONI ARIA marketing partners are Schering-Plough (Ireland) Company, a subsidiary of Merck & Co., Inc. and Mitsubishi Tanabe Pharma Corporation; TREMFYA discovered using MorphoSys AG antibody technology; JNJ-2113 was discovered through a collaboration with Protagonist Therapeutics – Janssen retains exclusive rights to develop and commercialize for a broad range of indications Neuroscience INVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/ TREVICTA/ INVEGA HAFYERA/ BYANNLI are subject to a technology license agreement from Alkermes Pharma Ireland Limited, and RISPERDAL CONSTA developed in collaboration with Alkermes, Inc. Infectious Diseases PREZCOBIX / REZOLSTA fixed-dose combination, SYMTUZA and ODEFSEY developed in collaboration with Gilead Sciences, Inc., and JULUCA and CABENUVA developed in collaboration with ViiV Healthcare UK. Research and development activities for the Company’s COVID-19 vaccine, including the ENSEMBLE clinical trial and the delivery of doses for the U.S., have been funded in part with federal funds from the U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (BARDA), under Contract No. HHSO100201700018C, and in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) at the U.S. Department of Health and Human Services (HHS) Cardiovascular/ Metabolism/Other INVOKANA/ INVOKAMET/ VOKANAMET/ INVOKAMET XR fixed-dose combination licensed from Mitsubishi Tanabe Pharma Corporation; XARELTO co-developed with Bayer HealthCare AG; PROCRIT/ EPREX licensed from Amgen Inc., and X-Linked Retinitis Pigmentosa: AAV-RPGR licensed from MeiraGTx Oncology IMBRUVICA developed in collaboration and co-marketed in the U.S. with Pharmacyclics, LLC, an AbbVie company; ZYTIGA licensed from BTG International Ltd.; VELCADE developed in collaboration with Millennium: The Takeda Oncology Company; DARZALEX and DARZALEX FASPRO licensed from Genmab A/S, BALVERSA licensed and discovered in collaboration with Astex Pharmaceuticals, Inc.; ERLEADA licensed from Regents of California and Memorial Sloan Kettering; CARVYKTI licensed and developed in collaboration with Legend Biotech USA Inc. and Legend Biotech Ireland Limited, niraparib licensed from TESARO, Inc., an oncology-focused business within GSK, lazertinib licensed from Yuhan Corporation, DuoBody platform licensed from Genmab A/S relates to several bispecific antibody programs, ENHANZE platform licensed from Halozyme Therapeutics, Inc. Pulmonary Hypertension UPTRAVI license and supply agreement with Nippon Shinyaku (co-promotion in Japan), and OPSUMIT co-promotion agreement with Nippon Shinyaku in Japan Global Public Health Janssen’s Monovalent Ebola Vaccine is developed in collaboration with Bavarian Nordic A/S, and MVA-BN-Filo® is licensed-in from Bavarian Nordic A/S. The program has benefited from funding and preclinical services from the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, NIAID support included 2 product development contracts starting in 2008 and 8 pre-clinical services contracts. This program is also receiving funding from the IMI2 Joint Undertaking under EBOVAC1 (grant nr. 115854), EBOVAC2 (grant nr. 115861), EBOVAC3 (grant nr. 800176), EBOMAN (grant nr. 115850) and EBODAC (grant nr. 115847). The IMI2 Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations (EFPIA). Further funding for the Ebola vaccine regimen has been provided by BARDA, within the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response, under Contract Numbers HHSO100201700013C and HHSO100201500008C. The initial work on Ebola was conducted which was extended from 2002 until 2011. 2002 and 2007 via a Cooperative Research and Development Agreement (CRADA is AI-0114) between Janssen/Crucell and the Vaccine Research Center (VRC)/NIAID, part of the NIH. Janssen/Crucell have licenses to much of VRC’s Ebola IP specific for human adenovirus under the Ad26/Ad35 Ebola vaccine CRADA invention. VAC69120 (Filovirus multivalent vaccine) developed in collaboration with Bavarian Nordic; funding: NIH Division of Microbiology and Infectious Diseases (DMID), under Contract Number HHSN272200800056C. Strategic Partnerships, Collaborations & Licensing Arrangements 4 During the course of this presentation, we will discuss a number of products and compounds developed in collaboration with strategic partners or licensed from other companies. The following is an acknowledgement of those relationships: -- 4 of 30 -- 5 Agenda CEO Remarks Enterprise Highlights Sales Performance and Earnings Review Capital Allocation and Guidance Q&A 1 2 3 4 5 Joaquin Duato Chairman of the Board and Chief Executive Officer Joseph J. Wolk Executive Vice President, Chief Financial Officer Erik Haas Worldwide Vice President, Litigation Jessica Moore Vice President, Investor Relations -- 5 of 30 -- Joaquin Duato Chairman of the Board and Chief Executive Officer -- 6 of 30 -- -- 7 of 30 -- -- 8 of 30 -- 9 Pharmaceutical • Regulatory: – Janssen Marks First Approval Worldwide for AKEEGA (Niraparib and Abiraterone Acetate Dual Action Tablet) with EC Authorisation for the Treatment of Patients with Metastatic Castration Resistant Prostate Cancer with BRCA1/2 Mutations – Milvexian Granted U.S. FDA Fast Track Designation for All Three Indications Under Evaluation in Phase 3 Librexia Program: Ischemic Stroke, Acute Coronary Syndrome and Atrial Fibrillation – Janssen Submits New Drug Application to U.S. FDA Seeking Approval of Investigational Single Tablet Combination Therapy of Macitentan and Tadalafil for Treatment of Patients with Pulmonary Arterial Hypertension (PAH) – Janssen Submits Supplemental Biologics License Application to U.S. FDA Seeking Approval of CARVYKTI for the Earlier Treatment of Patients with Relapsed or Refractory Multiple Myeloma • Data Release: – Janssen Reports First Results from Phase 2 SunRISe-1 Study of TAR-200 and Anti-PD-1 Antibody Cetrelimab in Patients with Bacillus Calmette-Guérin-Unresponsive Non-Muscle-Invasive Bladder Cancer – First Phase 3 TREMFYA (guselkumab) Data in Inflammatory Bowel Disease Show Positive Induction Results Among Patients with Moderately to Severely Active Ulcerative Colitis – Janssen to Highlight Scientific Advances and Commitment to Transform Cancer Care at ASCO and EHA with More than 90 Presentations Showcasing Robust, Differentiated Portfolio and Pipeline in Hematologic Malignancies and Solid Tumors – New Phase 2 Data Demonstrate Potential Benefit of Nipocalimab for Pregnant Individuals at High Risk of Early-Onset Severe Hemolytic Disease of the Fetus and Newborn (HDFN) – Janssen Announces Positive Topline Results for JNJ-2113—a Novel, First and Only Oral IL-23 Receptor Antagonist Peptide in Development for Moderate-to-Severe Plaque Psoriasis 2 – Treatment with RYBREVANT® (amivantamab-vmjw) Plus Chemotherapy Resulted in Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in Patients with Newly Diagnosed EGFR Exon 20 Insertion Mutation-Positive Non-Small Cell Lung Cancer2 • Other – Janssen Enters Worldwide Collaboration and License Agreement with Cellular Biomedicine Group to Develop Next Generation CAR-T Therapies MedTech • Data Release: – New Data Published on Biosense Webster QDOT MICRO Catheter – the Latest Advancement in Focal RF Ablation for Treating AFib Enterprise – Johnson & Johnson Announces Launch of Kenvue Inc. IPO Roadshow 1 These developments and all other news releases are available on the company’s website at news releases or JNJ.com news releases, as well as www.factsabouttalc.com, www.factsaboutourprescriptionopioids.com, and www.LTLManagementInformation.com 2 Subsequent to the Quarter Notable Announcements in the 2nd Quarter 1 -- 9 of 30 -- Jessica Moore Vice President, Investor Relations -- 10 of 30 -- Regional Sales Results Q2 2023 Q2 2022 % CHANGE Reported Operational1 U.S. $13.4 $12.2 10.2% 10.2% Europe 5.9 6.1 (3.1) (3.9) Western Hemisphere (ex U.S.) 1.7 1.5 11.5 17.7 Asia-Pacific, Africa 4.5 4.2 6.6 12.5 International 12.1 11.8 2.2 4.7 Worldwide (WW) $25.5 $24.0 6.3% 7.5% 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website Note: Values may not add due to rounding 2nd Quarter 2023 Sales Dollars in Billions 11 -- 11 of 30 -- $1.96 $1.80 $25.5 $24.0 $5.1 $4.8 8.1%; 9.7% 1 Q2 2023 Q2 2022 2nd Quarter 2023 Financial Highlights Dollars in Billions, except EPS Reported %; Operational % 1 12 Sales Adjusted Earnings 2 Adjusted EPS2 6.3%; 7.5% 1 GAAP Earnings 6.9% 6.5% Q2 2023 Q2 2022 8.9% Q2 2023 Q2 2023 Q2 2022 Q2 2022 Q2 2023 Q2 2022 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website 2 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules in the Investors section of the company's website Note: Fiscal second quarter Other (income) expense, net includes $37 million related to the Company's 10.4% non-controlling interest in Kenvue, Inc. from the time of the initial public offering on May 8, 2023 through the end of the fiscal second quarter. $2.80 $2.59 GAAP EPS $7.4 $6.9 -- 12 of 30 -- Immunology $4,496 Infectious Diseases $1,121 Neuroscience $1,793 Oncology $4,398 CVM/Other $950 PH $972 $13,731 3.1%, 3.8% WW Sales $MM ■ Reported Growth ■ Operational Growth 1 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website 2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules in the Investors section of the company's website Note: Values may not add due to rounding Key Drivers of Operational Performance1 Immunology • STELARA increase driven by market growth partially offset by unfavorable patient mix and rebates • Growth in TREMFYA due to share gains and market growth, partially offset by unfavorable patient mix • REMICADE decline due to biosimilar competition Infectious Diseases • COVID-19 Vaccine revenue decline Neuroscience • SPRAVATO growth driven by ongoing launches in the U.S. and Europe • Growth partially offset by declines from the paliperidone long-acting injectables, due to the XEPLION loss of exclusivity in EU Oncology • DARZALEX increase driven by share gains in all regions and continued market growth • Continued share gains and market growth in mCSPC, and increased penetration from new launches for ERLEADA • CARVYKTI increase driven by continued market share gains from ongoing launch • Growth partially offset by ZYTIGA loss of exclusivity and IMBRUVICA decline due to global competitive pressure. Imbruvica maintains its market leadership position Cardiovascular/ Metabolism/ Other (CVM/Other) • XARELTO increase due to favorable patient mix and market growth, partially offset by share loss Pulmonary Hypertension (PH) • Increase driven by favorable patient mix, share gains, and market growth from UPTRAVI and OPSUMIT • Continued declines in Other Pulmonary Hypertension Adjusted Operational Sales2: WW 3.9%, U.S. 9.2%, Int’l (2.2)% Pharmaceutical Highlights – 2nd Quarter 2023 Reported: WW 3.1%, U.S. 9.2%, Int’l (4.0)% Operational1: WW 3.8%, U.S. 9.2%, Int’l (2.5)% (2.2)%, (2.0)% 15.3%, 16.5% 8.8%, 9.7% (14.8)%, (16.6)% 1.9%, 2.6% Strong operational growth 1 of 6.2% excl. COVID-19 Vaccine driven by Oncology, Immunology, and PH 3.5%, 5.5% 13 -- 13 of 30 -- Key Drivers of Operational Performance1 Interventional Solutions • Electrophysiology: Double digit increase due to global procedure growth, new product performance (QDOT & OCTARAY) and commercial execution, partially offset by impacts from volume-based procurement in China (VBP impacts) • Abiomed: Acquired December 22, 2022; strength from all commercialized regions and continued adoption of Impella 5.5 and Impella RP Orthopaedics • Hips: Reflects global procedure growth and continued strength of the portfolio (primarily in the Anterior approach), partially offset by supply challenges • Trauma: Growth primarily driven by procedure recovery and adoption of recently launched products (Advanced Nailing Systems, Cannulated Compression Headless Screws, CrossRoads Extremity, and VA Clavicle) partially offset by VBP impacts • Knees: Reflects global procedure recovery, benefits from launches in the ATTUNE portfolio (Cementless & Medial Stabilized), and pull through related to the VELYS Robotic assisted solution, partially offset by supply constraints • Spine, Sports & Other: Primarily driven by procedure growth, positive uptake of new products (INHANCE & SYMPHONY), and growth in VELYS digital solutions, partially offset by VBP impacts and continued competitive pressures in Spine • Spine: ~ +2% WW, ~ -1% U.S., ~ +5% OUS Surgery • Advanced: • Endocutters: ~ +5% Growth primarily due to procedure recovery outside of the U.S. and uptake of recently launched products (ECHELON 3000, GST reloads, and ECHELON+), partially offset by VBP impacts, competitive pressures predominately in the U.S., and supply challenges • Biosurgery: ~ +18% Increase driven by global procedure growth and strength of the portfolio (SURGIFLO, SURGICEL Powder, and VISTASEAL) • Energy: ~ +3% Driven by procedure recovery outside of the U.S. and strength of new products (HD1000i), partially offset by VBP impacts and supply challenges • General: Growth primarily due to procedure recovery outside of the U.S. coupled with technology penetration and benefits from our differentiated Wound Closure portfolio (Barbed & PLUS Sutures) Vision • Contact Lenses/Other: Growth driven by continued strong performance of the ACUVUE OASYS 1-Day family (including recent launches of OASYS MAX 1-day and OASYS Multifocal), and commercial execution, partially offset by impacts from strategic portfolio decisions and supply challenges • Surgical: Reflects cataract procedure growth and continued strength of recent innovation (TECNIS EYHANCE), partially offset by softer Refractive and premium IOL markets Adjusted Operational Sales 2: WW 9.9%, U.S. 6.5%, Int’l 13.0% Orthopaedics $2,265 Surgery $2,594 Vision $1,308 Interventional Solutions $1,620 $7,788 12.9%, 14.7% WW Sales $MM ■ Reported Growth ■ Operational Growth 1 Exceptional operational growth 1 fueled by innovation and strong commercial execution across all franchises Reported: WW 12.9%, U.S. 14.6%, Int’l 11.3% Operational1: WW 14.7%, U.S. 14.6%, Int’l 14.7% 54.4%, 56.9% 5.4%, 6.9% 5.0%, 5.7% 5.9%, 8.4% 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website 2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules in the Investors section of the company's website Note: Values may not add due to rounding 14 MedTech Highlights – 2nd Quarter 2023 -- 14 of 30 -- OTC $1,659 Skin Health/Beauty $1,148 Oral Care $398 Baby Care $360 Women's Health $238 Wound Care/Other $207 $4,011 5.4%, 7.7% WW Sales $MM ■ Reported Growth ■ Operational Growth 1 Consumer Health Highlights – 2nd Quarter 2023 Operational growth 1 primarily driven by OTC Key Drivers of Operational Performance1 OTC • Growth driven by price actions, and strong TYLENOL and MOTRIN performance due to increased global Cough/Cold/Flu incidences Skin Health/ Beauty • Growth driven by price actions and strength in NEUTROGENA particularly in Sun, driven by innovation and supply repositioning Oral Care • Growth driven by price actions, partially offset by category deceleration in Asia and suspension of personal care sales in Russia Baby Care • Decline driven by competitive pressures in Asia, and suspension of personal care sales in Russia Women’s Health • Growth driven by price actions and continued strong growth in India, partially offset by suspension of personal care sales in Russia Wound Care/Other • Growth driven by price actions and innovation Adjusted Operational Sales2: WW 7.7%, U.S. 6.0%, Int’l 9.0% Reported: WW 5.4%, U.S. 6.0%, Int’l 5.0% Operational1: WW 7.7%, U.S. 6.0%, Int’l 9.0% 12.0%, 13.9% 3.4%, 10.0% 4.9%, 6.8% (4.0)%, (0.2)% 0.9%, 2.7% 2.0%, 3.5% 15 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website 2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules in the Investors section of the company's website Note: Values may not add due to rounding -- 15 of 30 -- 2023 2022 % Increase (Decrease) Amount % to Sales Amount % to Sales Sales to customers $25,530 100.0 $24,020 100.0 6.3 Cost of products sold 8,212 32.2 7,919 33.0 3.7 Gross Profit 17,318 67.8 16,101 67.0 7.6 Selling, marketing and administrative expenses 6,665 26.1 6,226 25.9 7.1 Research and development expense 3,829 15.0 3,703 15.4 3.4 Interest (income) expense, net (23) (0.1) (26) (0.1) Other (income) expense, net* (60) (0.2) 273 1.1 Restructuring 145 0.5 85 0.4 Earnings before provision for taxes on income 6,762 26.5 5,840 24.3 15.8 Provision for taxes on income 1,618 6.4 1,026 4.3 57.7 Net Earnings $5,144 20.1 $4,814 20.0 6.9 - Net earnings per share (Diluted) $1.96 $1.80 8.9 Average shares outstanding (Diluted) 2,625.7 2,667.9 Effective tax rate 23.9% 17.6% . Adjusted earnings before provision for taxes and net earnings 1 Earnings before provision for taxes on income $8,824 34.6 $8,171 34.0 8.0 Net earnings $7,358 28.8 $6,912 28.8 6.5 Net earnings per share (Diluted) $2.80 $2.59 8.1 Effective tax rate 16.6% 15.4% Condensed Consolidated Statement of Earnings 1 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules in the Investors section of the company's website * Fiscal second quarter Other (income) expense, net includes $37 million related to the Company's 10.4% non-controlling interest in Kenvue, Inc. from the time of the initial public offering on May 8, 2023 through the end of the fiscal second quarter. 16 2 nd Quarter 2023 (Unaudited; Dollar and Shares in Millions Except Per Share Figures) -- 16 of 30 -- 2023 2022 Adjusted Income Before Tax by Segment1 2 nd Quarter 2023 17 Pharmaceutical MedTech Consumer Health Expenses Not Allocated to Segments Q2 2023 Q2 2022 Pharmaceutical 42.7% 42.0% MedTech 28.6% 26.5% Consumer Health 23.5% 25.9% Total 34.6% 34.0% % to Sales ($0.2) ($0.2) $8.2B $5.6 $1.8 $1.0 $8.8B $5.9 $2.2 $0.9 2 1 Non-GAAP measure; excludes amortization expense and special items; see reconciliation schedules in the Investors section of the company's website 2 Estimated as of 7/20/2023 -- 17 of 30 -- Joseph J. Wolk Executive Vice President, Chief Financial Officer -- 18 of 30 -- 19 -- 19 of 30 -- Capital Allocation Strategy Capital Allocation Organic growth business needs Free cash flow1 Priorities are clear and remain unchanged Competitive dividends Share repurchases HIGHER PRIORITY LOWER PRIORITY Investment in M&A Dollars in Billions Q2 2023 Cash and Marketable Securities $29 Debt ($46) Net Debt* ($17) Free Cash Flow1,2 ~$5.4. Q2 2023: $3.8B invested in R&D $7.4B year-to-date $3.1B in dividends paid to shareholders; $6.0B year-to-date Note: values may have been rounded * Includes approximately $7B of Kenvue Net Debt 1 Non-GAAP measure; cash flow from operations less CAPEX 2 Estimated as of July 20, 2023. Cash flow from operations, the most directly comparable GAAP financial measure, will be included in subsequent SEC filings 3 Announced $5B share repurchase program on September 14, 2022 20 Note: values may have been rounded $2.5B in share repurchases year-to-date; 100% of the program completed 3 -- 20 of 30 -- 21 2023 Guidance Summary January Adjusted Operational EPS1 $10.50 Improved Performance Outlook 0.05 April Adjusted Operational EPS1 $10.55 Collaboration and License Agreement with Cellular Biomedicine Group (0.10) Kenvue Non-Controlling Interest (0.08) Improved Performance Outlook 0.28 New July Adjusted Operational EPS1 $10.65 Improved performance outlook driving higher adjusted operational earnings per share1 guidance 1 Non-GAAP measure; excludes the impact of translational currency; excludes intangible amortization expense and special items Note: Adjusted Operational EPS figures reflect midpoint of issued guidance -- 21 of 30 -- 1 Non-GAAP measure; excludes acquisitions and divestitures 5 Sales less: COGS, SM&A and R&D expenses 2 Non-GAAP measure; excludes the impact of translational currency 6 Excludes COVID-19 Vaccine 3 Euro Average Rate: July 2023 = $1.09; Euro Spot Rate: July 2023 = $1.10 7 Includes $200MM of non-controlling interest 4 Non-GAAP measure; excludes intangible amortization expense and special items Note: Percentages may be rounded 22 2023 P&L Guidance July April Comments Adjusted Operational Sales1,2,6 6.0% - 7.0% 4.5% - 5.5% Increasing midpoint to 6.5% Operational Sales 2,6 $99.3B - $100.3B 7.0% - 8.0% $97.9B - $98.9B 5.5% - 6.5% Increasing midpoint by $1.4B to 7.5% Estimated Reported Sales 3,6 $98.8B - $99.8B 6.5% - 7.5% $97.9B - $98.9B 5.5% - 6.5% Increasing midpoint by $0.9B to 7.0% Incremental FX ($0.5B) Adjusted Pre-Tax Operating Margin4,5 Slight Improvement Approximately flat Increasing primarily due to expense management Net Other Income 4 $1.6 - $1.8 billion 7 $1.9 - $2.1 billion Reducing to account for non-controlling interest in Kenvue Inc. Net Interest Expense / (Income) $150 - $250 million $250 - $350 million Reducing due to interest income on net proceeds from Kenvue separation Effective Tax Rate 4 15.5% - 16.5% 15.5% - 16.5% Maintaining Adjusted EPS (Operational) 2,4 $10.60 - $10.70 4.5% - 5.5% $10.50 - $10.60 3.5% - 4.5% Maintain range; Increasing midpoint by $0.10 Adjusted EPS (Reported) 3,4 $10.70 - $10.80 5.5% - 6.5% $10.60 - $10.70 4.5% - 5.5% Maintain range; Increasing midpoint by $0.10 Raising top- and bottom-line guidance due to strong Q2 performance -- 22 of 30 -- MedTech • Anticipate normal seasonality and stable procedure volumes and staffing levels for the balance of the year • Expect continued competitive performance, continued uptake of recently launched products, and improving supply • Potential for accelerated back half headwinds from volume-based procurement and international sanctions Pharmaceutical • Continue to anticipate another year of above-market adjusted operational sales growth • Expect slightly higher operational sales growth in the second half of the year compared to the first half • Anticipate continued uptake of newly launched products Consumer Health • Lapping prior year price increases in the back half of the year 2023 Phasing Considerations 1 Non-GAAP measure; excludes acquisitions and divestitures 4 Excludes COVID-19 Vaccine 2 Non-GAAP measure; excludes the impact of translational currency Note: Percentages may be rounded 3 Euro Average Rate: July 2023 = $1.09; Euro Spot Rate: July 2023 = $1.10 July April Adjusted Operational Sales1,2,4 6.0% - 7.0% 4.5% - 5.5% Operational Sales2,4 $99.3B - $100.3B 7.0% - 8.0% $97.9B - $98.9B 5.5% - 6.5% Estimated Reported Sales3,4 $98.8B - $99.8B 6.5% - 7.5% $97.9B - $98.9B 5.5% - 6.5% 23 -- 23 of 30 -- 24 Driving Meaningful Value Creation Pharmaceutical Growth of existing assets Upcoming pipeline advancements Regulatory and clinical milestones Continued uptake of newly launched products MedTech Commercial execution Upcoming pipeline advancements Exposure to higher growth markets Driving continued adoption of recently launched products -- 24 of 30 -- 25 Additional Q2 2023 Highlights -- 25 of 30 -- Reminder: Save the Date Introducing Our First Ever… Enterprise Business Review Focused on the New Johnson & Johnson Tuesday, December 5, 2023 New York Stock Exchange -- 26 of 30 -- Erik Haas Worldwide Vice President, Litigation -- 27 of 30 -- Q&A Erik Haas Worldwide Vice President, Litigation Chairman of the Board and Chief Executive Officer Joaquin Duato Joseph J. Wolk Executive Vice President, Chief Financial Officer Jessica Moore Vice President, Investor Relations -- 28 of 30 -- -- 29 of 30 -- -- 30 of 30 --